Bicycle Therapeutics PLC - ESG Rating & Company Profile powered by AI
The Disclosure score covers 17 United Nations Sustainable Development Goals including: 'Affordable & Clean Energy', 'Decent Work & Economic Growth' and 'Life below Water'. Complete ESG analysis of Bicycle Therapeutics PLC are accessed by signing up for free. The assessment of Bicycle Therapeutics PLC uses data from across the internet and also from public disclosures by Bicycle Therapeutics PLC.
Bicycle Therapeutics PLC in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.9; made up of an environmental score of 8.0, social score of 8.0 and governance score of 4.8.
6.9
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
290 | Qiagen NV | 7.0 | High |
290 | WuXi AppTec Co Ltd | 7.0 | High |
294 | Bicycle Therapeutics PLC | 6.9 | High |
294 | Cabaletta Bio Inc | 6.9 | High |
294 | AnGes Inc | 6.9 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Bicycle Therapeutics PLC have an accelerator or VC vehicle to help deliver innovation?
Does Bicycle Therapeutics PLC disclose current and historical energy intensity?
Does Bicycle Therapeutics PLC report the average age of the workforce?
Does Bicycle Therapeutics PLC reference operational or capital allocation in relation to climate change?
Does Bicycle Therapeutics PLC disclose its ethnicity pay gap?
Does Bicycle Therapeutics PLC disclose cybersecurity risks?
Does Bicycle Therapeutics PLC offer flexible work?
Does Bicycle Therapeutics PLC have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Bicycle Therapeutics PLC disclose the number of employees in R&D functions?
Does Bicycle Therapeutics PLC conduct supply chain audits?
Does Bicycle Therapeutics PLC disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Bicycle Therapeutics PLC conduct 360 degree staff reviews?
Does Bicycle Therapeutics PLC disclose the individual responsible for D&I?
Does Bicycle Therapeutics PLC disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Bicycle Therapeutics PLC disclose current and / or historical scope 2 emissions?
Does Bicycle Therapeutics PLC disclose water use targets?
Does Bicycle Therapeutics PLC have careers partnerships with academic institutions?
Did Bicycle Therapeutics PLC have a product recall in the last two years?
Does Bicycle Therapeutics PLC disclose incidents of discrimination?
Does Bicycle Therapeutics PLC allow for Work Councils/Collective Agreements to be formed?
Has Bicycle Therapeutics PLC issued a profit warning in the past 24 months?
Does Bicycle Therapeutics PLC disclose parental leave metrics?
Does Bicycle Therapeutics PLC disclose climate scenario or pathway analysis?
Does Bicycle Therapeutics PLC disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Bicycle Therapeutics PLC disclose the pay ratio of women to men?
Does Bicycle Therapeutics PLC support suppliers with sustainability related research and development?
Does Bicycle Therapeutics PLC disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Bicycle Therapeutics PLC reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Bicycle Therapeutics PLC involved in embryonic stem cell research?
Does Bicycle Therapeutics PLC disclose GHG and Air Emissions intensity?
Does Bicycle Therapeutics PLC disclose its waste policy?
Does Bicycle Therapeutics PLC report according to TCFD requirements?
Does Bicycle Therapeutics PLC disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Bicycle Therapeutics PLC disclose energy use targets?
Does Bicycle Therapeutics PLC disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Bicycle Therapeutics PLC have a policy relating to cyber security?
Have a different question?
Potential Risks for Bicycle Therapeutics PLC
These potential risks are based on the size, segment and geographies of the company.
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.